Therefore, our findings uncover an intimate relationship between CDK1 and oxaliplatin resistance, which provides a preclinical rationale for targeting CDK1 as a therapeutic strategy for patients with oxaliplatin‐resistant CRC. The gene discussed is CDK1; the disease is colorectal carcinoma.